| Jul 31 |
INmune Bio Q2 2024 Earnings Preview
|
| Jul 29 |
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
|
| Jul 23 |
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
|
| Jul 12 |
INmune and Elevai Labs amend licensing deal
|
| Jul 12 |
Shareholders Will Probably Be Cautious Of Increasing INmune Bio, Inc.'s (NASDAQ:INMB) CEO Compensation At The Moment
|
| Jul 8 |
INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro
|
| Jun 28 |
INmune Bio’s unique Alzheimer’s trial endpoint receives validation
|
| Jun 27 |
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
|
| May 30 |
INmune Bio to join Russell 3000 Index
|
| May 30 |
INmune Bio Inc. to Join Russell 3000® Index
|
